Efavirenz to Nevirapine Switch in HIV-1–Infected Patients with Dyslipidemia: A Randomized, Controlled Study
Epidemiologie, Systemes d'Informations, Modelisation, Institut National de la Sante et de la Recherche Medicale U707, Paris, France. Clinical Infectious Diseases
(Impact Factor: 8.89).
08/2007; 45(2):263-6. DOI: 10.1086/518973
Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P < .04). A switch to nevirapine was associated with no severe adverse events. © 2007 by the Infectious Diseases Society of America. All rights reserved.
Available from: PubMed Central
- "We found that exposure to nevirapine was associated with protection from liver steatosis. Others have reported that nevirapine can effect favorable lipid changes
[21-23], but efavirenz did not favorably affected lipid metabolism in vivo. In a randomized clinical trial, lipid profiles improved when efavirenz was switched to nevirapine
[Show abstract] [Hide abstract]
ABSTRACT: Since Highly Active Antiretroviral Therapy (HAART) medications were made available in 2002, multiple serious side effects have been observed. However, no study has yet systematically evaluated the prevalence of liver steatosis, a very serious but treatable side effect.Objectives: This study examined the prevalence of and independent risk factors for liver steatosis in Chinese HIV-infected, HAART-experienced patients who had been diagnosed with hypertriglyceridemia.
In this cross-sectional observational study, the prevalence of liver steatosis was determined by ultrasound imaging that detected diffusion in hepatic echogenicity. The risk factors associated with steatosis were evaluated with a proportional odds logistic regression model.
Among 163 HIV-infected patients with hypertriglyceridemia and past HAART experience, 75(46%) patients were determined to have liver steatosis. In multivariable logistic regression model, the risk factors associated with liver steatosis were: higher triglyceride level (OR = 1.086,P = 0.026), metabolic syndromes (OR = 2.092,P = 0.024) and exposure to nucleoside reverse transcriptase inhibitor (NRTIs) ( (OR = 2.11,P = 0.001) and Stavudine (OR = 3.75,P = 0.01)). Exposure to Nevirapine (OR = 0 .41, P = 0.003) was a favorable factor for lipid metabolism in vivo and was a protective factors for liver steatosis.
Chinese HIV-infected patients with hypertriglyceridemia appear to be prone to liver steatosis, especially those on NRTIs. Routine screening should be considered on their lipid panels.
Virology Journal 08/2013; 10(1):261. DOI:10.1186/1743-422X-10-261 · 2.18 Impact Factor
Available from: Laura Carenzi
- " More recently, switch from efavirenz to nevirapine has also become a relevant hypothesis, since the former has always shown to be unable to revert PI-induced metabolic alterations  and has been associated with a certain degree of such side effects. Switching to nevirapine in such reports was associated with decreases in LDL-Cholesterol and increases in HDL, as well as with a reduction of neuropsychiatric effects [40, 78]. Viral suppression was maintained in all switchers and in one study also two initially viremic patients suppressed passing to nevirapine . "
[Show abstract] [Hide abstract]
ABSTRACT: Many infections favor or are directly implicated with lipid metabolism perturbations and/or increased risk of coronary heart disease (CHD). HIV itself has been shown to increase lipogenesis in the liver and to alter the lipid profile, while the presence of unsafe habits, addiction, comorbidities, and AIDS-related diseases increases substantially the risk of cardiovascular disease (CVD) in the HIV-infected population. Antiretroviral therapy reduces such stimuli but many drugs have intrinsic toxicity profiles impacting on metabolism or potential direct cardiotoxicity. In a moment when the main guidelines of HIV therapy are predating the point when to start treating, we mean to highlight the contribution of HIV-1 to lipid alteration and inflammation, the impact of antiretroviral therapy, the decisions on what drugs to use to reduce the probability of having a cardiovascular event, the increasing
use of statins and fibrates in HIV-1 infected subjects, and finally the switch strategies, that balance effectiveness and toxicity to move the decision to change HIV drugs. Early treatment might reduce the negative effect of HIV on overall cardiovascular risk but may also evidence the impact of drugs, and the final balance (reduction or increase in CHD and lipid abnormalities) is not known up to date.
Cholesterol 10/2010; 2010(2090-1283):271504. DOI:10.1155/2010/271504
Available from: Kang Cheng
[Show abstract] [Hide abstract]
ABSTRACT: Three dimensional (3-D) quantum mechanical models of ion movements
in a cylindrical ion-channel, based on a steady state Schrodinger
equation in a single particle system and in a time independent field,
ore improved in this study. The improved models elucidate that: ions,
going through a cylindrical channel, travel in the longitudinal (x)
direction and wave as well as are free and trapped in an infinite deep
potential energy web in the transversal (r and θ) directions. A
quantum mechanical model of a single channel current can be derived from
the model of ions' movements in the longitudinal (x) direction.
Experimental data of a single channel current can be parameterly fitted
well with the model. The ions' radical waves obey Bessel functions of
the first kind of order I with a parameter k<sub>n</sub> and it has a
solution: R(r)=B J<sub>1</sub> (r k<sub>n</sub>), where a is a constant,
n=1, 2, 3, ..., and 0, 1, 2, 3, ... . The highest probability that an
ion con be found In a cross section within a cylindrical ion-channel is
on or close to the longitudinal axis according to the principle of the
minimum energy state. The ions' angular waves are: Θ(θ)=c
<sub>1</sub> exp(110)-c<sub>2</sub> exp(-110), where, c<sub>1</sub> and
c<sub>2</sub> are constants, and l=0, 1, 2, 3 ... . These results are
consistent with the previous results obtained from 3-D quantum
mechanical models of ion movements in a cuboidal ion-channel and those
macroscopic descriptions represented with classic theory of fluid
Biomedical Engineering Conference, 1997., Proceedings of the 1997 Sixteenth Southern; 05/1997
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.